Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Heron Therapeutics (0J4V) Share Price & Analysis

0J4V Stock Chart & Stats

$0.28-$0.02(-5.03%)
At close: 4:30 PM GMT
$0.3$0.4$0.53 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$0.28 - $0.28
52-Week Range
$0.26 - $1.57
Previous Close
$0.30
Volume
393
Average Volume (3M)
17.13K
Market Cap
$52.72M
Enterprise Value
$187.97M
Total Cash (Recent Filing)
$42.66M
Total Debt (Recent Filing)
$148.35M
Price to Earnings (P/E)
―
Beta
1.70
Next Earnings
Nov 09, 2026 (Est.)
EPS Estimate
-0.03
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Margin Improvement

Strong top-line growth combined with a high gross margin indicates improving commercial traction and meaningful contribution potential from existing products. If maintained, this operating profile can support reinvestment, gradual scale benefits, and progress toward sustainable profitability over the next several quarters.

APONVIE Adoption

Rapid APONVIE growth, broader account penetration, and rising surgical NK-1 share show that Heron is building a durable acute-care franchise. The expanding base of P&T approvals and covered procedures provides a foundation for continued adoption beyond a single quarter.

Portfolio Expansion Through Licensing

The Long Grove licensing agreement broadens Heron's potential U.S. product portfolio and extends its commercial platform beyond current brands. Partnering may provide additional revenue opportunities while sharing development and commercialization responsibilities, supporting longer-term diversification.

Bears Say

Highly Leveraged Balance Sheet

Very high leverage relative to the equity base leaves Heron with limited financial flexibility and increases sensitivity to operating setbacks. Required principal payments and covenant requirements can constrain investment in sales growth, product development, and other strategic priorities.

CINVANTI Generic-entry Risk

Potential generic competition threatens the durability of CINVANTI revenue and market share, especially because the product is Heron's largest contributor. Even with an appeal and defensive strategy, uncertain timing and pricing pressure could materially weaken cash generation and planning visibility.

Persistent Losses And Cash Burn

Heron remains dependent on external financing or further spending reductions because operations are not yet self-funding. Continued net losses and negative free cash flow reduce resilience, make debt obligations harder to absorb, and limit the resources available for sustained commercial expansion.

Heron Therapeutics News

0J4V FAQ

What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest share price was $0.26 and its highest was $1.57 in the past 12 months.
What is Heron Therapeutics’s market cap?
Heron Therapeutics’s market cap is $52.72M.
When is Heron Therapeutics’s upcoming earnings report date?
Heron Therapeutics’s next earnings report is estimated for Nov 09, 2026 (not yet confirmed), which is in 7 days.
How were Heron Therapeutics’s earnings last quarter?
Heron Therapeutics released its earnings results on Aug 10, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of -$0.005 by -$0.025.
Is Heron Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Heron Therapeutics pay dividends?
Heron Therapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of ―. See more information on Heron Therapeutics dividends here
What is Heron Therapeutics’s EPS estimate?
Heron Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Heron Therapeutics have?
Heron Therapeutics has 189,852,310 shares outstanding.
What happened to Heron Therapeutics’s price movement after its last earnings report?
Heron Therapeutics reported an EPS of -$0.03 in its last earnings report, missing expectations of -$0.005. Following the earnings report the stock price went down -24.431%.
Which hedge fund is a major shareholder of Heron Therapeutics?
Hedge funds hold Heron Therapeutics shares: the largest hedge-fund position in Heron Therapeutics is 1,299,100,773 shares.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology